Research and analysis

Mpox: transmission, infectious and incubation periods, and isolation guidance

These rapid reviews identify and summarise evidence relating to mpox (clade II) transmission, infectious and incubation periods, and adherence and barriers to following isolation guidance.

Documents

Mpox: transmission, and infectious and incubation periods

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Mpox: adherence and barriers to following isolation guidance

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Two rapid reviews were conducted to identify and summarise evidence relating to:

  • mpox (clade II) transmission
  • mpox infectious and incubation periods
  • adherence and barriers to following isolation guidance for mpox

1. The first review, with research up to 15 August 2022, includes:

  • one review for pre-2022 outbreaks
  • 30 studies from 2022 on the transmission of mpox
  • no studies on mpox infectious periods
  • 8 studies on mpox incubation periods
  • 21 studies from 2022 for whether environmental or individual samples contained mpox DNA or live monkeypox virus

2. The second review searched up to 15 August 2022 for primary studies related to guidance for mpox (any guidance from any country) and includes 3 studies reporting on 2 online surveys.

Updates to this page

Published 2 March 2023

Sign up for emails or print this page